X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ibrutinib (1485) 1485
humans (733) 733
oncology (618) 618
hematology (605) 605
chronic lymphocytic-leukemia (364) 364
chronic lymphocytic leukemia (342) 342
rituximab (325) 325
leukemia, lymphocytic, chronic, b-cell - drug therapy (288) 288
cll (282) 282
leukemia (280) 280
female (253) 253
male (253) 253
open-label (252) 252
lymphomas (239) 239
aged (225) 225
lymphoma (223) 223
cancer (213) 213
btk (207) 207
idelalisib (202) 202
middle aged (189) 189
survival (179) 179
therapy (179) 179
tyrosine (174) 174
bruton's tyrosine kinase (164) 164
hemic and lymphatic diseases (161) 161
activation (159) 159
pyrimidines - therapeutic use (158) 158
mutation (157) 157
animals (156) 156
chemotherapy (156) 156
patients (156) 156
mantle cell lymphoma (155) 155
antineoplastic agents - therapeutic use (153) 153
pyrazoles - therapeutic use (153) 153
venetoclax (151) 151
protein-tyrosine kinases - antagonists & inhibitors (142) 142
pharmacology & pharmacy (139) 139
care and treatment (136) 136
chronic lymphatic leukemia (134) 134
brutons tyrosine kinase (130) 130
targeting btk (127) 127
treatment outcome (125) 125
pyrimidines - pharmacology (124) 124
kinases (121) 121
aged, 80 and over (120) 120
b-cell receptor (120) 120
leukemia, lymphocytic, chronic, b-cell - pathology (120) 120
fludarabine (119) 119
protein-tyrosine kinase (119) 119
adult (118) 118
lymphocytes b (118) 118
initial therapy (117) 117
apoptosis (116) 116
protein kinase inhibitors - therapeutic use (116) 116
antineoplastic combined chemotherapy protocols - therapeutic use (113) 113
pyrazoles - pharmacology (113) 113
cyclophosphamide (109) 109
inhibitor (109) 109
abridged index medicus (106) 106
pci-32765 (106) 106
expression (100) 100
resistance (100) 100
signal transduction (98) 98
pyrimidines - administration & dosage (97) 97
cell line, tumor (93) 93
pyrazoles - administration & dosage (93) 93
lymphatic leukemia (91) 91
prognosis (91) 91
protein kinase inhibitors - pharmacology (90) 90
b-cell lymphoma (88) 88
mice (86) 86
bruton tyrosine kinase (84) 84
immunotherapy (84) 84
drug therapy (83) 83
antineoplastic agents - pharmacology (82) 82
immune system diseases (82) 82
clinical trials (81) 81
leukemia, lymphocytic, chronic, b-cell - genetics (81) 81
pyrimidines - adverse effects (81) 81
signal transduction - drug effects (81) 81
protein-tyrosine kinases - metabolism (80) 80
tyrosine kinase inhibitor (80) 80
analysis (79) 79
pyrazoles - adverse effects (79) 79
medicine & public health (76) 76
lenalidomide (75) 75
chronic lymphocytic leukaemia (74) 74
cell biology (73) 73
lymphoma, mantle-cell - drug therapy (73) 73
multicenter (72) 72
research (71) 71
receptor (69) 69
immunology (67) 67
review (66) 66
previously untreated patients (65) 65
diagnosis (64) 64
biochemistry & molecular biology (63) 63
risk factors (63) 63
inhibitors (62) 62
minimal residual disease (62) 62
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1568) 1568
German (30) 30
Russian (18) 18
French (13) 13
Czech (5) 5
Spanish (5) 5
Japanese (3) 3
Hungarian (2) 2
Polish (2) 2
Chinese (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Haematology, ISSN 0007-1048, 03/2015, Volume 168, Issue 5, pp. 701 - 707
Summary CXCR4WHIM frameshift and nonsense mutations follow MYD88L265P as the most common somatic variants in Waldenström Macroglobulinaemia (WM), and impact... 
ibrutinib | CXCR4 | Waldenström macroglobulinaemia | WHIM | MYD88 | Ibrutinib
Journal Article
Clinical infectious diseases, ISSN 1537-6591, 2018, Volume 67, Issue 5, pp. 687 - 692
Abstract Background Ibrutinib is a Bruton tyrosine kinase inhibitor that is used for the treatment of lymphoid cancers, including chronic lymphocytic leukemia,... 
ibrutinib | infection | invasive fungal infection | INFECTIOUS DISEASES | X-LINKED AGAMMAGLOBULINEMIA | MICROBIOLOGY | INVASIVE FUNGAL-INFECTIONS | IMMUNOLOGY | TARGETING BTK | SINGLE-AGENT IBRUTINIB | BRUTONS TYROSINE KINASE | TREATMENT-NAIVE | THERAPY | PNEUMOCYSTIS-JIROVECII PNEUMONIA | B-CELL MALIGNANCIES | CHRONIC LYMPHOCYTIC-LEUKEMIA | and Commentaries
Journal Article
Blood, ISSN 0006-4971, 11/2016, Volume 128, Issue 18, pp. 2193 - 2194
Journal Article
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 98, pp. 37173 - 37184
Earlier we have shown the expression of a constitutively active receptor tyrosine kinase Axl in CLL B-cells from previously untreated CLL patients, and that... 
CLL | TP-0903 | AXL | Ibrutinib | Apoptosis
Journal Article
Journal Article
Journal Article
British journal of haematology, ISSN 0007-1048, 2017, Volume 178, Issue 1, pp. 81 - 93
Summary Cortactin (CTTN) is a substrate of the Src kinase Lyn that is known to play an actin cytoskeletal regulatory role involved in cell migration and cancer... 
Cortactin | matrix metalloproteinase‐9 | chronic lymphocytic leukaemia | B‐cell receptor and Ibrutinib | B-cell receptor and Ibrutinib | matrix metalloproteinase-9 | INVADOPODIA | CLL | PHOSPHORYLATION | METALLOPROTEINASE | IBRUTINIB | REGULATOR | MICROENVIRONMENT | MALIGNANCIES | EXTRACELLULAR-MATRIX DEGRADATION | HEMATOLOGY | EXPRESSION | Pyrazoles - therapeutic use | Humans | Middle Aged | Neoplasm Proteins - physiology | Male | Antineoplastic Agents - therapeutic use | Cell Movement - physiology | Matrix Metalloproteinase 9 - metabolism | Proto-Oncogene Proteins c-bcr - physiology | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | src-Family Kinases - physiology | Phosphorylation - drug effects | Tumor Cells, Cultured | Pyrazoles - pharmacology | Cell Cycle Checkpoints - physiology | Pyrimidines - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Receptors, CXCR4 - physiology | Pyrimidines - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Signal Transduction - physiology | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Cortactin - physiology | Protein-Tyrosine Kinases - antagonists & inhibitors | Muscle proteins | B cells | Cell culture | Phosphorylation | CXCL12 protein | Leukocyte migration | Leukemia | Matrix metalloproteinase | Lymph nodes | Cell adhesion & migration | Reduction (metal working) | Signal transduction | Pathways | Actin | Peripheral blood | Metalloproteinase | Chronic lymphatic leukemia | siRNA | Src protein | Patients | Bruton's tyrosine kinase | CXCR4 protein | Gelatinase B | Signaling | Inhibitors | Lymphocytes B | Cytoskeleton | In vitro methods and tests | Cell migration | Cancer
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 8/2015, Volume 21, Issue 16, pp. 3705 - 3715
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 2017, Volume 15, Issue 5, pp. 835 - 847
Summary Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an effective therapeutic agent for multiple... 
ibrutinib | blood platelets | agammaglobulinemia | lymphoma | hemorrhage | CONTROLLED-TRIAL | THROMBUS FORMATION | X-LINKED AGAMMAGLOBULINEMIA | ATRIAL-FIBRILLATION | SINGLE-AGENT IBRUTINIB | BRUTONS TYROSINE KINASE | ACALABRUTINIB ACP-196 | B-CELL MALIGNANCIES | CHRONIC LYMPHOCYTIC-LEUKEMIA | PERIPHERAL VASCULAR DISEASE | PLATELET GLYCOPROTEIN-VI | HEMATOLOGY | Anticoagulants - administration & dosage | Risk Assessment | Pyrimidines - administration & dosage | Humans | Risk Factors | Hemorrhage - prevention & control | Protein Kinase Inhibitors - adverse effects | Anticoagulants - adverse effects | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Animals | Drug Interactions | Blood Coagulation - drug effects | Signal Transduction - drug effects | Antineoplastic Agents - adverse effects | Blood Platelets - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Pyrimidines - adverse effects | Hemorrhage - chemically induced | Blood Platelets - drug effects | Drug Substitution | Platelet Aggregation Inhibitors - adverse effects | Pyrazoles - adverse effects | Tyrosine | Anticoagulants | Aspirin | Antiinflammatory agents | Fish oils | Immunoproliferative diseases | Antagonists | Inflammation | Hemorrhage | Bruton's tyrosine kinase | Bleeding | Chemotherapy | Lymphocytes B | Vitamin E | Nonsteroidal anti-inflammatory drugs | Protein-tyrosine kinase | Vitamin K | Bruton type agammaglobulinemia | Lymphoma | Ibrutinib | Blood Platelets
Journal Article
Molecular cancer, ISSN 1476-4598, 2018, Volume 17, Issue 1, pp. 57 - 23
Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of... 
Chronic lymphocytic leukemia | Tumor microenvironment | B cell receptor signaling | Leukemia | Chemokine receptor | B cell development | Bruton's tyrosine kinase | Lymphoma | Ibrutinib | SIGNALING PATHWAYS | BIOCHEMISTRY & MOLECULAR BIOLOGY | X-LINKED AGAMMAGLOBULINEMIA | FACTOR-KAPPA-B | ATRIAL-FIBRILLATION | BTK INHIBITOR IBRUTINIB | TEC KINASE | ONCOLOGY | THERAPEUTIC TARGET | CHRONIC LYMPHOCYTIC-LEUKEMIA | TUMOR-ASSOCIATED MACROPHAGES | BETA-GAMMA-SUBUNITS | Leukemia, B-Cell - metabolism | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Tumor Microenvironment | Leukemia, B-Cell - etiology | Receptors, Antigen, B-Cell - metabolism | Molecular Targeted Therapy | Biomarkers, Tumor | Cell Differentiation - genetics | Agammaglobulinaemia Tyrosine Kinase - metabolism | Cell Transformation, Neoplastic - genetics | Leukemia, B-Cell - drug therapy | Agammaglobulinaemia Tyrosine Kinase - chemistry | B-Lymphocytes - pathology | Gene Expression Regulation, Neoplastic - drug effects | Lymphoma, B-Cell - etiology | Bone Marrow | B-Lymphocytes - metabolism | Lymphoma, B-Cell - drug therapy | Lymphoma, B-Cell - metabolism | Lymphopoiesis - ethics | Leukemia, B-Cell - pathology | Treatment Outcome | Cell Transformation, Neoplastic - metabolism | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Lymphoma, B-Cell - pathology | Agammaglobulinaemia Tyrosine Kinase - genetics | Protein Kinase Inhibitors - pharmacology | Care and treatment | Usage | Lymphomas | Research | Chemokines | Cancer | Bruton’s tyrosine kinase
Journal Article